Crux Wealth Advisors Acquires 4,120 Shares of Ardelyx, Inc. $ARDX

Crux Wealth Advisors boosted its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX) by 17.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,393 shares of the biopharmaceutical company’s stock after buying an additional 4,120 shares during the quarter. Crux Wealth Advisors’ holdings in Ardelyx were worth $107,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. grew its position in Ardelyx by 79.6% during the second quarter. Harbor Capital Advisors Inc. now owns 233,248 shares of the biopharmaceutical company’s stock valued at $914,000 after buying an additional 103,385 shares during the period. AQR Capital Management LLC grew its position in Ardelyx by 188.5% during the first quarter. AQR Capital Management LLC now owns 1,573,063 shares of the biopharmaceutical company’s stock valued at $7,724,000 after buying an additional 1,027,814 shares during the period. Millennium Management LLC grew its position in Ardelyx by 118.2% during the first quarter. Millennium Management LLC now owns 6,465,262 shares of the biopharmaceutical company’s stock valued at $31,744,000 after buying an additional 3,501,782 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Ardelyx during the first quarter valued at approximately $673,000. Finally, GAMMA Investing LLC grew its position in Ardelyx by 1,342.0% during the first quarter. GAMMA Investing LLC now owns 5,912 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 5,502 shares during the period. 58.92% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on ARDX shares. Wedbush restated an “outperform” rating and set a $14.00 target price (up from $13.00) on shares of Ardelyx in a research report on Tuesday, August 5th. UBS Group set a $12.00 price target on shares of Ardelyx in a research report on Tuesday, August 5th. Wall Street Zen upgraded shares of Ardelyx from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Piper Sandler upped their price target on shares of Ardelyx from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ardelyx in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.70.

Ardelyx Price Performance

ARDX stock opened at $5.03 on Monday. Ardelyx, Inc. has a one year low of $3.21 and a one year high of $6.78. The company’s fifty day moving average price is $5.89 and its 200-day moving average price is $4.81. The company has a debt-to-equity ratio of 1.44, a quick ratio of 4.03 and a current ratio of 4.30. The company has a market capitalization of $1.21 billion, a PE ratio of -21.87 and a beta of 0.67.

Ardelyx (NASDAQ:ARDX) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.05. Ardelyx had a negative net margin of 14.60% and a negative return on equity of 36.57%. The firm had revenue of $97.66 million for the quarter, compared to the consensus estimate of $82.69 million. During the same quarter in the previous year, the firm earned ($0.07) earnings per share. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. On average, equities analysts anticipate that Ardelyx, Inc. will post -0.18 EPS for the current fiscal year.

Insider Transactions at Ardelyx

In other news, insider Eric Duane Foster sold 15,308 shares of the business’s stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $5.93, for a total value of $90,776.44. Following the transaction, the insider owned 301,498 shares of the company’s stock, valued at approximately $1,787,883.14. The trade was a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Laura A. Williams sold 80,000 shares of the business’s stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $6.12, for a total transaction of $489,600.00. Following the completion of the transaction, the insider directly owned 366,322 shares in the company, valued at $2,241,890.64. This trade represents a 17.92% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 165,551 shares of company stock valued at $996,917. 4.80% of the stock is owned by corporate insiders.

Ardelyx Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.